Should COVID-19 be branded to Viral Thrombotic Fever?

Costa Filho, R. C.; Faria Neto, Hugo Caire C.; Mengel, J.; Pelajo-Machado, M.; Martins, M. A.; Leite, E. T.; Mendonça Filho, H. T. F.; Souza, T. A. C. Brasil de; Bentacor, G. B.; Galiardi, J. P. Leite

This article is a Preprint

Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.

Should COVID-19 be branded to Viral Thrombotic Fever?

Costa Filho, R. C.; Faria Neto, Hugo Caire C.; Mengel, J.; Pelajo-Machado, M.; Martins, M. A.; Leite, E. T.; Mendonça Filho, H. T. F.; Souza, T. A. C. Brasil de; Bentacor, G. B.; Galiardi, J. P. Leite.

Affiliation

Costa Filho, R. C.; Hospital Pró-Cardíaco. Founder and coordinator of Department of Critical Care. Americas Medical Services. United Health Group. Rio de Janeiro, RJ, Brasil..

Fundação Oswaldo Cruz. Instituto Oswaldo Cruz.; .

Preprint in En | PREPRINT-FIOCRUZ | ID: ppf-46941

Key words

COVID-19; SARS-CoV-2; Febre; SARS COV Mpro; Endotélio; Inflamação; Coagulação; Trombose; Hipercoagulabilidade; Endothelium; COVID-19; SARS-CoV-2; Fever; NETs; Inflammation; Coagulation; roTEM; Hypercoagulability; Thrombosis

Fulltext

Add to My VHL

XML

Search on Google